Khedezla（desvenlafaxine，去甲文拉法辛缓释片）获FDA批准
7月10日，美国FDA批准的Khedezla（desvenlafaxine，去甲文拉法辛缓释片）用于治疗严重抑郁症。
Khedezla内含有5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）去甲文拉法辛，它也是Pristiq的活性成分，Pristiq在2008年获得FDA批准，所含的为去甲文拉法辛琥珀酸盐。
Khedezla有50毫克和100毫克两种剂量规格，每日服用一次。
以Khedezla治疗的患者中最常见的不良反应有恶心、头晕、失眠、多汗、便秘、嗜睡、食欲下降、焦虑和男性性功能障碍。
Khedezla由Osmotica制药公司委托AAIPharma生产。
KHEDEZLA Rx 
 Generic Name and Formulations:
Desvenlafaxine 50mg, 100mg; ext-rel tabs.

Company:
Par Pharmaceutical, Inc.
Indications for KHEDEZLA:
Major depressive disorder.

Adult Dose for KHEDEZLA:
Swallow whole. 50mg once daily. Moderate renal impairment: max 50mg/day. Severe renal impairment (CrCl <30mL/min), ESRD: max 50mg every other day. Do not give supplemental dose after dialysis. Moderate-to-severe hepatic impairment: max 100mg/day. Withdraw gradually.

Children's Dose for KHEDEZLA:
Not established.

Pharmacological Class:
Serotonin and norepinephrine reuptake inhibitor.

Contraindications:
Allow ≥14 days after MAOI discontinuance before starting desvenlafaxine; allow ≥7 days after desvenlafaxine discontinuance before starting an MAOI. Concomitant linezolid, IV methylene blue.

Warnings/Precautions:
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Pre-existing hypertension. Monitor BP before and during treatment; consider dose reduction or discontinuation if elevated BP persists. Cardio- or cerebrovascular disease. Increased risk of bleeding events. Increased intraocular pressure or risk of angle-closure glaucoma; monitor. History of mania/hypomania. Severe renal dysfunction. Seizure disorder. Reeva luate periodically. Write ℞ for smallest practical amount. Elderly. Pregnancy (Cat.C; avoid in 3rd trimester). Nursing mothers: not recommended.

Interactions:
See Contraindications. Avoid alcohol, concomitant venlafaxine, other forms of desvenlafaxine. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant NSAIDs, aspirin, anticoagulants; monitor. May be affected by CYP2D6 substrates.

Adverse Reactions:
Nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, specific male sexual dysfunction; rare: hyponatremia (esp. in elderly), interstitial lung disease, eosinophilic pneumonia, serotonin syndrome, mydriasis.

How Supplied:
Tabs—30, 90